Jeff Vacirca Buys 31,050 Shares of Caris Life Sciences (NASDAQ:CAI) Stock

Caris Life Sciences, Inc. (NASDAQ:CAI) Director Jeff Vacirca purchased 31,050 shares of the business’s stock in a transaction dated Monday, May 11th. The shares were purchased at an average cost of $16.15 per share, for a total transaction of $501,457.50. Following the completion of the purchase, the director directly owned 49,671 shares of the company’s stock, valued at approximately $802,186.65. This represents a 166.75% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Caris Life Sciences Price Performance

Caris Life Sciences stock opened at $15.94 on Tuesday. The firm has a 50 day moving average price of $19.04. The firm has a market capitalization of $4.51 billion and a P/E ratio of -2.09. Caris Life Sciences, Inc. has a 1 year low of $15.70 and a 1 year high of $42.50. The company has a debt-to-equity ratio of 0.66, a current ratio of 7.85 and a quick ratio of 7.35.

Caris Life Sciences (NASDAQ:CAI) last posted its earnings results on Thursday, February 26th. The company reported $0.28 EPS for the quarter, topping the consensus estimate of $0.01 by $0.27. Caris Life Sciences had a net margin of 3.75% and a return on equity of 102.71%. The business had revenue of $292.89 million for the quarter, compared to the consensus estimate of $281.00 million. During the same period last year, the company earned ($1.73) EPS. The firm’s revenue was up 125.4% compared to the same quarter last year. Equities analysts anticipate that Caris Life Sciences, Inc. will post 0.12 EPS for the current year.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on CAI shares. Wall Street Zen downgraded Caris Life Sciences from a “buy” rating to a “hold” rating in a report on Saturday, May 2nd. Robert W. Baird set a $22.00 target price on Caris Life Sciences in a report on Friday. BTIG Research decreased their price target on Caris Life Sciences from $38.00 to $32.00 and set a “buy” rating for the company in a research note on Friday. Canaccord Genuity Group lowered their price objective on Caris Life Sciences from $30.00 to $22.00 and set a “hold” rating for the company in a research report on Friday, March 13th. Finally, New Street Research initiated coverage on Caris Life Sciences in a research note on Friday. They issued a “market perform” rating on the stock. Six analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $27.56.

Institutional Investors Weigh In On Caris Life Sciences

Large investors have recently added to or reduced their stakes in the business. Global Retirement Partners LLC increased its holdings in Caris Life Sciences by 99,900.0% in the fourth quarter. Global Retirement Partners LLC now owns 1,000 shares of the company’s stock worth $27,000 after purchasing an additional 999 shares in the last quarter. PNC Financial Services Group Inc. grew its position in shares of Caris Life Sciences by 839.4% during the 1st quarter. PNC Financial Services Group Inc. now owns 1,644 shares of the company’s stock worth $29,000 after buying an additional 1,469 shares during the period. Olistico Wealth LLC bought a new stake in shares of Caris Life Sciences in the 4th quarter valued at $31,000. Fifth Third Bancorp bought a new stake in shares of Caris Life Sciences in the 1st quarter valued at $31,000. Finally, Sterling Capital Management LLC lifted its position in shares of Caris Life Sciences by 128.3% during the 1st quarter. Sterling Capital Management LLC now owns 1,927 shares of the company’s stock valued at $34,000 after acquiring an additional 1,083 shares during the period.

About Caris Life Sciences

Caris Life Sciences (NASDAQ: CAI) is a molecular science company focused on advancing precision medicine in oncology. The company develops and delivers comprehensive molecular profiling services designed to identify actionable biomarkers across DNA, RNA and protein modalities. Its clinical services are intended to support oncologists in treatment decision-making by matching patients to targeted therapies, immunotherapies and relevant clinical trials based on tumor biology.

Caris provides laboratory-based diagnostic testing and related interpretive reports, combining high-throughput sequencing and other molecular technologies with bioinformatic analysis.